Location: New York, NY
CIK: 0001263508 · Show all filings
Period: Q3 2025 (← Previous) (Next →)
Filing Date: Nov 14, 2025
Total Value: $13.84B (99.7% shares, 0.3% debt)
| Ticker | Issuer | Shares | Value | % | Est. Cost | Unrealized | Class | CUSIP |
|---|---|---|---|---|---|---|---|---|
| ONC | BeOne Medicines Ltd. | 8,799,053 | $2.998B | 21.7% | $136.93 | — | SPONSORED ADS | 07725L102 |
| INCY | Incyte Corporation | 30,743,663 | $2.607B | 18.8% | $72.80 | +8.6% | COM | 45337C102 |
| MDGL | Madrigal Pharmaceuticals, Inc. | 2,141,701 | $982M | 7.1% | $139.37 | +167.7% | COM | 558868105 |
| INSM | Insmed Incorporated | 6,703,484 | $965M | 7.0% | $57.51 | +113.0% | COM PAR $.01 | 457669307 |
| ACAD | ACADIA Pharmaceuticals Inc. | 42,896,690 | $915M | 6.6% | $18.93 | +24.9% | COM | 004225108 |
| SMMT | Summit Therapeutics Inc. | 33,722,974 | $697M | 5.0% | $10.51 | +130.8% | COM | 86627T108 |
| RYTM | Rhythm Pharmaceuticals, Inc. | 5,604,483 | $566M | 4.1% | $23.49 | +295.3% | COM | 76243J105 |
| RVMD | Revolution Medicines, Inc. | 9,455,357 | $442M | 3.2% | $29.36 | +33.4% | COM | 76155X100 |
| CELC | Celcuity Inc. | 7,915,792 | $391M | 2.8% | $21.19 | +88.9% | COM | 15102K100 |
| KYMR | Kymera Therapeutics, Inc. | 6,651,429 | $376M | 2.7% | $28.76 | +56.8% | COM | 501575104 |
| KOD | Kodiak Sciences Inc. | 17,310,490 | $283M | 2.0% | $30.30 | -71.6% | COM | 50015M109 |
| ALKS | Alkermes plc | 8,091,351 | $243M | 1.8% | $26.84 | +5.1% | SHS | G01767105 |
| ABCL | AbCellera Biologics Inc. | 27,525,640 | $138M | 1.0% | $21.02 | -79.0% | COM | 00288U106 |
| EWTX | Edgewise Therapeutics, Inc. | 7,305,940 | $119M | 0.9% | $14.29 | -0.8% | COM | 28036F105 |
| KNSA | Kiniksa Pharmaceuticals International, plc | 2,824,669 | $110M | 0.8% | $18.73 | +73.4% | ORD SHS CL A | G52694109 |
| STOK | Stoke Therapeutics, Inc. | 4,633,838 | $109M | 0.8% | $9.30 | +84.2% | COM | 86150R107 |
| IMTX | Immatics N.V. | 12,094,094 | $103M | 0.7% | $8.55 | -28.0% | SHS | N44445109 |
| GRAL | GRAIL, Inc. | 1,630,125 | $96.39M | 0.7% | $16.26 | +135.0% | COM | 384747101 |
| IDYA | IDEAYA Biosciences, Inc. | 3,275,444 | $89.12M | 0.6% | $19.47 | +24.2% | COM | 45166A102 |
| IMVT | Immunovant, Inc. | 5,457,881 | $87.98M | 0.6% | $22.96 | -29.5% | COM | 45258J102 |
| IMCR | Immunocore Holdings plc | 2,322,656 | $84.38M | 0.6% | $38.09 | — | ADS | 45258D105 |
| BCYC | Bicycle Therapeutics plc | 10,885,357 | $84.25M | 0.6% | $20.78 | — | SPONSORED ADS | 088786108 |
| RARE | Ultragenyx Pharmaceutical Inc. | 2,772,692 | $83.4M | 0.6% | $52.13 | -42.5% | COM | 90400D108 |
| ABVX | Abivax S.A. | 875,796 | $74.36M | 0.5% | $84.90 | — | SPONSORED ADS | 00370M103 |
| ARWR | Arrowhead Pharmaceuticals, Inc. | 1,670,762 | $57.62M | 0.4% | $17.69 | +24.3% | COM | 04280A100 |
| ROIV | Roivant Sciences Ltd. | 3,767,773 | $57.01M | 0.4% | $9.71 | +27.4% | SHS | G76279101 |
| DNLI | Denali Therapeutics Inc. | 3,731,695 | $54.18M | 0.4% | $23.78 | -39.6% | COM | 24823R105 |
| — | Merus N.V. | 574,377 | $54.08M | 0.4% | $52.94 | — | COM | N5749R100 |
| NTLA | Intellia Therapeutics, Inc. | 2,746,674 | $47.44M | 0.3% | $10.05 | +22.5% | COM | 45826J105 |
| REPL | Replimune Group, Inc. | 11,045,336 | $46.28M | 0.3% | $14.45 | -55.8% | COM | 76029N106 |
| RAPP | Rapport Therapeutics, Inc. | 1,547,090 | $45.95M | 0.3% | $15.27 | +16.8% | COM | 75383L102 |
| GPCR | Structure Therapeutics Inc. | 1,556,109 | $43.57M | 0.3% | $22.23 | — | SPONSORED ADS | 86366E106 |
| — | Celcuity Inc. | 30,750,000 | $40.91M | 0.3% | $1.33 | — | Note 2.75% 8/1/2031 | 15102KAA8 |
| VRDN | Viridian Therapeutics, Inc. | 1,744,406 | $37.64M | 0.3% | $13.57 | +32.9% | COM | 92790C104 |
| IONS | Ionis Pharmaceuticals, Inc. | 566,798 | $37.08M | 0.3% | $48.82 | 0.0% | COM | 462222100 |
| PRAX | Praxis Precision Medicines, Inc. | 689,488 | $36.54M | 0.3% | $44.22 | +9.6% | COM | 74006W207 |
| GLUE | Monte Rosa Therapeutics, Inc. | 4,916,095 | $36.43M | 0.3% | $6.49 | -18.4% | COM | 61225M102 |
| BNTX | BioNTech SE | 368,923 | $36.38M | 0.3% | $107.38 | — | SPONSORED ADS | 09075V102 |
| NRIX | Nurix Therapeutics, Inc. | 3,882,125 | $35.87M | 0.3% | $22.27 | -53.4% | COM | 67080M103 |
| DNTH | Dianthus Therapeutics, Inc. | 789,759 | $31.08M | 0.2% | $18.76 | +36.2% | COM | 252828108 |
| TRDA | Entrada Therapeutics, Inc. | 4,865,819 | $28.22M | 0.2% | $16.96 | — | COM | 29384C108 |
| ARGX | argenx SE | 37,760 | $27.85M | 0.2% | $79.01 | — | SPONSORED ADR | 04016X101 |
| RNAM | Avidity Biosciences, Inc. | 625,000 | $27.23M | 0.2% | $40.43 | 0.0% | COM | 05370A108 |
| PCVX | Vaxcyte, Inc. | 640,885 | $23.08M | 0.2% | $76.85 | -56.9% | COM | 92243G108 |
| IRON | Disc Medicine, Inc. | 337,050 | $22.27M | 0.2% | $49.46 | +20.3% | COM | 254604101 |
| — | Cidara Therapeutics, Inc. | 227,272 | $21.76M | 0.2% | $48.71 | — | COM | 171757206 |
| CLDX | Celldex Therapeutics, Inc. | 665,370 | $17.21M | 0.1% | $23.17 | +0.0% | COM | 15117B202 |
| NGNE | Neurogene Inc. | 991,691 | $17.19M | 0.1% | $19.35 | +3.8% | COM | 64135M105 |
| SERA | Sera Prognostics, Inc. | 5,498,170 | $16.82M | 0.1% | $3.09 | -8.0% | CLASS A COM | 81749D107 |
| SYRE | Spyre Therapeutics, Inc. | 1,000,000 | $16.76M | 0.1% | $15.36 | +6.2% | COM | 00773J202 |
| CERS | Cerus Corporation | 10,008,345 | $15.91M | 0.1% | $4.19 | -67.7% | COM | 157085101 |
| — | Akero Therapeutics, Inc. | 324,630 | $15.41M | 0.1% | $32.79 | — | COM | 00973Y108 |
| XENE | Xenon Pharmaceuticals Inc. | 370,208 | $14.86M | 0.1% | $19.37 | +81.8% | COM | 98420N105 |
| DBVT | DBV Technologies S.A. | 1,461,425 | $14.61M | 0.1% | $3.09 | — | SPONSORED ADS | 23306J309 |
| PRLD | Prelude Therapeutics Inc. | 10,123,824 | $14.58M | 0.1% | $28.24 | -96.5% | COM | 74065P101 |
| ACLX | Arcellx, Inc. | 166,825 | $13.7M | 0.1% | $62.26 | +15.6% | COMMON STOCK | 03940C100 |
| CTMX | CytomX Therapeutics, Inc. | 4,250,826 | $13.56M | 0.1% | $1.73 | +30.4% | COM | 23284F105 |
| TSHA | Taysha Gene Therapies, Inc. | 4,004,756 | $13.1M | 0.1% | $1.91 | +47.9% | COM SHS | 877619106 |
| XNCR | Xencor, Inc. | 1,102,106 | $12.93M | 0.1% | $16.65 | -47.9% | COM | 98401F105 |
| DSGN | Design Therapeutics, Inc. | 1,712,882 | $12.9M | 0.1% | $12.06 | -58.5% | COM | 25056L103 |
| NUVL | Nuvalent, Inc. | 143,937 | $12.45M | 0.1% | $73.17 | +8.1% | COM | 670703107 |
| SION | Sionna Therapeutics, Inc. | 400,000 | $11.76M | 0.1% | $16.34 | +33.1% | COM | 829401108 |
| CRNX | Crinetics Pharmaceuticals, Inc. | 280,000 | $11.66M | 0.1% | $30.88 | +3.5% | COM | 22663K107 |
| VKTX | Viking Therapeutics, Inc. | 366,083 | $9.621M | 0.1% | $29.83 | 0.0% | COM | 92686J106 |
| PHVS | Pharvaris N.V. | 375,000 | $9.356M | 0.1% | $22.18 | 0.0% | COM | N69605108 |
| AGIO | Agios Pharmaceuticals, Inc. | 189,866 | $7.621M | 0.1% | $30.31 | +24.1% | COM | 00847X104 |
| SANA | Sana Biotechnology, Inc. | 2,030,949 | $7.21M | 0.1% | $4.55 | -20.6% | COM | 799566104 |
| SGMT | Sagimet Biosciences Inc. | 952,996 | $6.538M | 0.0% | $9.53 | -14.9% | COM SER A | 786700104 |
| ALMS | Alumis Inc. | 1,562,500 | $6.234M | 0.0% | $13.30 | -69.0% | COM | 022307102 |
| RLAY | Relay Therapeutics, Inc. | 1,160,117 | $6.056M | 0.0% | $13.78 | -72.3% | COM | 75943R102 |
| SKYE | Skye Bioscience, Inc. | 1,450,638 | $5.701M | 0.0% | $7.74 | -51.2% | COM | 83086J200 |
| HRTX | Heron Therapeutics, Inc. | 4,251,951 | $5.357M | 0.0% | $1.59 | 0.0% | COM | 427746102 |
| TCRX | TScan Therapeutics, Inc. | 2,784,792 | $5.068M | 0.0% | $6.08 | -70.9% | COM | 89854M101 |
| MBX | MBX Biosciences, Inc. | 277,777 | $4.861M | 0.0% | $13.37 | 0.0% | COM | 55287L101 |
| VTVT | vTv Therapeutics, Inc. | 148,314 | $3.463M | 0.0% | $14.29 | +21.1% | CL A | 918385204 |
| VTYX | Ventyx Biosciences, Inc. | 1,023,130 | $3.182M | 0.0% | $2.65 | 0.0% | COM | 92332V107 |
| LBRX | LB Pharmaceuticals Inc. | 200,000 | $3.158M | 0.0% | $15.87 | 0.0% | COM SHS | 50180M108 |
| VIR | Vir Biotechnology, Inc. | 542,539 | $3.098M | 0.0% | $7.89 | -35.2% | COM | 92764N102 |
| WVE | Wave Life Sciences Ltd. | 344,063 | $2.519M | 0.0% | $5.98 | +35.4% | SHS | Y95308105 |
| ELVN | Enliven Therapeutics, Inc. | 114,833 | $2.351M | 0.0% | $15.34 | +31.4% | COM | 29337E102 |
| TARA | Protara Therapeutics, Inc. | 536,832 | $2.335M | 0.0% | $13.35 | -75.7% | COM STK | 74365U107 |
| TECX | Tectonic Therapeutic, Inc. | 100,000 | $1.569M | 0.0% | $32.59 | -36.7% | COM | 878972108 |
| KALA | KALA BIO, Inc. | 985,093 | $1.507M | 0.0% | $7.72 | +28.5% | COM | 483119202 |
| — | Generation Bio Co. | 194,493 | $1.19M | 0.0% | $6.12 | — | COM | 37148K209 |
| CTNM | Contineum Therapeutics, Inc. | 77,670 | $913K | 0.0% | $16.10 | -49.9% | CL A | 21217B100 |
| ALGS | Aligos Therapeutics, Inc. | 83,055 | $814K | 0.0% | $12.44 | -26.5% | COM | 01626L204 |
| VYNE | VYNE Therapeutics Inc. | 851,353 | $285K | 0.0% | $0.65 | 0.0% | COM | 92941V308 |
| TYRA | Tyra Biosciences, Inc. | 10,607 | $148K | 0.0% | $12.95 | -11.9% | COM | 90240B106 |
| ACRV | Acrivon Therapeutics, Inc. | 22,809 | $41,284 | 0.0% | $4.64 | -69.7% | COMMON STOCK | 004890109 |
| SRZNW | Surrozen, Inc. | 833,333 | $14,833 | 0.0% | $1.14 | — | W EXP 8/11/2026 | 86889P117 |
| OPTEY | Opthea Limited | 2,087,320 | $0 | 0.0% | $11.12 | — | SPONSORED ADS | 68386J208 |